Silvia Vanni
Overview
Explore the profile of Silvia Vanni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gabellone S, Vanni S, Fausti V, Miserocchi G, Liverani C, Spadazzi C, et al.
Heliyon
. 2024 Dec;
10(23):e40596.
PMID: 39687122
Objectives: Gastrointestinal stromal tumors, the most prevalent mesenchymal tumors (80 %) of the gastrointestinal tract, comprise less than 1 % of all gastrointestinal neoplasms and about 5 % of all...
2.
Calabrese C, Miserocchi G, De Vita A, Spadazzi C, Cocchi C, Vanni S, et al.
Obes Rev
. 2024 Sep;
25(12):e13833.
PMID: 39289899
The adipose tissue is a complex organ that can play endocrine, metabolic, and immune regulatory roles in cancer. In particular, adipocytes provide metabolic substrates for cancer cell proliferation and produce...
3.
Vanni S, Miserocchi G, Gallo G, Fausti V, Gabellone S, Liverani C, et al.
Exp Hematol Oncol
. 2024 Aug;
13(1):74.
PMID: 39103896
Soft tissue sarcomas represent an heterogeneous group of rare mesenchymal tumors comprising 1% of all solid malignancies. Among them, liposarcoma is one of the most common histotypes with atypical lipomatous...
4.
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, et al.
Eur J Cancer
. 2024 Jul;
208:114129.
PMID: 39002347
Background: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies....
5.
Recine F, Vanni S, Bongiovanni A, Fausti V, Mercatali L, Miserocchi G, et al.
Front Immunol
. 2024 Jul;
15:1378398.
PMID: 38983859
Immunotherapy has emerged as promising treatment in sarcomas, but the high variability in terms of histology, clinical behavior and response to treatments determines a particular challenge for its role in...
6.
Guerrieri A, Bellotti C, Penzo M, Columbaro M, Pannella M, De Vita A, et al.
BMC Cancer
. 2023 Dec;
23(1):1194.
PMID: 38057796
Background: Myxofibrosarcoma is a rare malignant soft tissue sarcoma characterised by multiple local recurrence and can become of higher grade with each recurrence. Consequently, myxofibrosarcoma represents a burden for patients,...
7.
Lucarelli E, De Vita A, Bellotti C, Frisoni T, Vanni S, Guerrieri A, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958307
Myxofibrosarcoma (MFS) is a malignant soft tissue sarcoma (STS) that originates in the body's connective tissues. It is characterized by the presence of myxoid (gel-like) and fibrous components and typically...
8.
Miserocchi G, Bassi M, De Luca G, Calpona S, De Rosa F, Bongiovanni A, et al.
Front Oncol
. 2023 Oct;
13:1245043.
PMID: 37795450
Background: Polymorphous adenocarcinoma (PAC) represents the second most widespread neoplasm of the minor salivary glands. These tumors rarely develop a histological progression from low-grade to high-grade malignancy, named "high-grade transformation"...
9.
Vanni S, Fausti V, Fonzi E, Liverani C, Miserocchi G, Spadazzi C, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108089
Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one of the most common adult soft tissue sarcoma (STS) of...
10.
Fausti V, De Vita A, Vanni S, Ghini V, Gurrieri L, Riva N, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831421
A second-line standard of treatment has not yet been identified in patients with soft tissue sarcomas (STS), so identifying predictive markers could be a valuable tool. Recent studies have shown...